COMMUNIQUÉS West-GlobeNewswire

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

13/01/2025 - 17:00

- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three major market Phase [...]

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

13/01/2025 - 17:00

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January [...]

ProMIS Neurosciences Issues Letter to Shareholders

13/01/2025 - 16:30

CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics [...]

Baylor Genetics to Integrate with Epic Aura to Enhance Efficiency and Deliver Genetic Testing Results to Hospitals and Health Systems

13/01/2025 - 16:00

The company will be the first to integrate whole genome sequencing (WGS) into Epic's Aura platform, further advancing access to genetic insights for patients and providers in the neonatal and pediatric intensive care [...]

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

13/01/2025 - 15:27

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance triggers $16.7 million [...]

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

13/01/2025 - 15:16

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated [...]

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

13/01/2025 - 15:15

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune [...]

Positron Corporation Engages Skyline Corporate Communications Group, LLC to Enhance Investor Relations and Financial Community Outreach

13/01/2025 - 15:15

Niagara Falls, NY, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission [...]

Avance Clinical Leads as the CRO of Choice for Early Phase Clinical Trials in Australia – Announced at Biotech Showcase 2025

13/01/2025 - 15:07

WAKE FOREST, N.C. and ADELAIDE, Australia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avance Clinical , a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical [...]

HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

13/01/2025 - 15:01

DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced estimates of HSAs, HSA [...]

Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors

13/01/2025 - 15:00

PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments to the Vaso management [...]

NeurAxis Inc. Issues Letter to Shareholders

13/01/2025 - 15:00

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

13/01/2025 - 15:00

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE [...]

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

13/01/2025 - 15:00

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in [...]

VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025

13/01/2025 - 15:00

CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with [...]

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

13/01/2025 - 15:00

Reports $709 million in preliminary 1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE ® U.S. net product revenues, including $167 million in 4Q 2024 $98 million in EMPAVELI ® U.S. net product revenues, [...]

Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period

13/01/2025 - 15:00

Robust plan benefits powered member growth, mainly driven by switchers from other plans Company will focus on balancing profitability with strategic investments in growth and technology to take advantage of strong [...]

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

13/01/2025 - 15:00

Fourth Quarter 2024 worldwide revenue of ~ $48.8 to $49.0 million representing growth of ~26% Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, [...]

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

13/01/2025 - 15:00

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients CTAs [...]